AstraZeneca PLC American Depositary Shares (AZN) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q2 26	$1.25	$1.32	+5.6%	—	$15.4B	—
Q1 26	$1.27	$1.29	+1.6%	—	$15.3B	—
Q2 25	$0.88	$0.79	-10.2%	—	$14.5B	—
Q1 25	$1.12	$1.25	+11.6%	—	$13.6B	—
Q4 24	$1.04	$1.05	+1.0%	—	$14.9B	—
Q3 24	$1.03	$1.04	+1.0%	—	$13.6B	—
Q2 24	$0.99	$0.99	0.0%	—	$12.9B	—
Q1 24	$0.95	$1.03	+8.4%	—	$12.7B	—
Q4 23	$0.76	$0.73	-3.9%	—	$12B	—
Q3 23	$0.82	$0.87	+6.1%	—	$11.5B	—
Q2 23	$0.97	$1.08	+11.3%	—	$11.4B	—
Q1 23	$0.82	$0.96	+17.1%	—	$10.9B	—
Q4 22	$0.68	$0.69	+1.5%	—	$11.2B	—
Q3 22	$0.75	$0.84	+12.0%	—	$11B	—
Q2 22	$1.04	$0.86	-17.3%	—	$10.8B	—
Q1 22	$1.15	$0.95	-17.4%	—	$11.4B	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	$6.6	—	—	$58.7B	—
FY24	—	$4.54	—	—	$54.1B	—
FY23	—	$1.92	—	—	$45.8B	—
FY22	—	$1.06	—	—	$44.4B

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$23B	$22.5B	$22.1B	$24.4B	$26.6B	$37.4B	$44.4B	$45.8B	$54.1B	$58.7B
YoY change	-6.9%	-2.33%	-1.67%	+10.4%	+9.16%	+40.6%	+18.5%	+3.29%	+18%	+8.63%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	23B	22.5B	22.1B	24.4B	26.6B	37.4B	44.4B	45.8B	54.1B	58.7B
Cost of revenue	4.1B	4.3B	4.9B	4.9B	5.3B	12.4B	12.4B	8.3B	10.2B	10.6B
Gross profit	18.9B	18.1B	17.2B	19.5B	21.3B	25B	32B	37.5B	43.9B	48.1B
Gross margin	82.1%	80.8%	77.7%	79.8%	80.1%	66.8%	72.1%	82%	81.1%	81.9%
Research & development	5.9B	5.8B	5.9B	6.1B	6B	9.7B	9.8B	10.9B	13.6B	14.2B
Selling, general & administrative	9.7B	10.5B	11B	12B	11.9B	15.6B	18B	18.2B	20.2B	20.8B
Operating expenses	15.8B	16.5B	17B	18.2B	18B	25.6B	27.9B	29.3B	33.9B	35.1B
Operating income	3.6B	2.1B	516M	1.7B	3.9B	-139M	4.5B	8.7B	10.3B	13.3B
Operating margin	15.5%	9.13%	2.34%	7.13%	14.7%	-0.37%	10.2%	19%	19%	22.7%
Non-operating income, net	—	—	—	—	—	—	—	—	—	—
Pretax income	3.6B	2.2B	2B	1.5B	3.9B	-265M	2.5B	6.9B	8.7B	12.4B
Income tax	146M	-641M	-57M	321M	772M	-380M	-792M	938M	1.6B	2.2B
Net income	3.4B	2.9B	2B	1.2B	3.1B	115M	3.3B	6B	7B	10.2B
Net margin	14.8%	12.8%	9.28%	5.03%	11.8%	0.31%	7.42%	13%	13%	17.4%
EBITDA	6B	5B	4.2B	5.5B	6.8B	3.9B	9.8B	13.9B	15.6B	19.1B
EPS	1.39	1.19	0.85	0.52	1.22	0.04	1.06	1.92	4.54	6.6
Diluted EPS	1.38	1.19	0.85	0.52	1.22	0.04	1.05	1.91	4.5	6.54

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	11.5B	12B	12.7B	12.9B	13.6B	14.9B	13.6B	14.5B	15.2B	15.5B	15.3B	15.4B
Cost of revenue	2.1B	2.3B	2.2B	2.2B	3.1B	2.7B	2.2B	2.5B	2.8B	3.1B	2.7B	2.5B
Gross profit	9.4B	9.7B	10.5B	10.8B	10.5B	12.2B	11.3B	12B	12.4B	12.4B	12.6B	12.9B
Gross margin	81.8%	80.8%	82.5%	83.1%	77.3%	81.7%	83.5%	82.9%	81.6%	79.9%	82.5%	83.6%
Research & development	2.6B	3.1B	2.8B	3B	3.1B	4.7B	3.2B	3.5B	3.7B	3.9B	3.5B	4.1B
Selling, general & administrative	4.9B	4B	4.6B	5.1B	5.3B	5.6B	4.6B	5B	5.2B	5.6B	5.1B	5.8B
Operating expenses	7.4B	7.1B	7.4B	8.1B	8.4B	10.2B	7.8B	8.5B	8.8B	9.5B	8.6B	9.7B
Operating income	2B	2B	3.1B	2.7B	2.1B	2B	3.7B	3.5B	3.6B	3B	4.2B	3.2B
Operating margin	17%	16.7%	24.6%	21.2%	15.5%	13.7%	27%	24.3%	23.6%	19.2%	27.8%	20.6%
Non-operating income, net	—	—	—	—	—	—	—	—	—	—	—	—
Pretax income	1.7B	897M	2.8B	2.4B	1.8B	1.7B	3.4B	3.1B	3.2B	2.6B	3.9B	2.8B
Income tax	274M	-62M	620M	469M	395M	166M	481M	679M	709M	300M	833M	291M
Net income	1.4B	959M	2.2B	1.9B	1.4B	1.5B	2.9B	2.4B	2.5B	2.3B	3.1B	2.5B
Net margin	12%	7.98%	17.2%	14.9%	10.6%	10.1%	21.5%	16.9%	16.7%	15%	20.2%	16.3%
EBITDA	3.3B	2.9B	4.5B	4.1B	4.1B	2.8B	5B	5B	5.2B	4.4B	5.7B	5.2B
EPS	0.45	0.31	0.7	0.62	0.46	0.97	1.88	1.58	0.82	1.5	1.99	1.61
Diluted EPS	0.44	0.31	0.7	0.62	0.46	0.96	1.87	1.57	0.81	1.49	1.97	1.61

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	138.2B	175.7B	192.5B	259.5B	262.3B	330.4B	419.8B	417.3B	—	285B	257.7B
Enterprise value	149.2B	189B	206B	271.5B	274.7B	354.8B	442.8B	440.1B	—	308.4B	285.8B
Shares outstanding	2.5B	2.5B	2.5B	2.6B	2.6B	2.8B	3.1B	3.1B	1.6B	1.6B	1.6B

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	40.6	61.3	93.9	211.5	83.4	2.9K	127.5	70	—	27.8	24.8
P/S	6.01	7.82	8.71	10.6	9.86	8.83	9.47	9.11	—	4.85	4.21
P/B	8.29	10.6	13.7	17.8	16.8	8.41	11.3	10.7	—	5.85	5.14
EV/EBITDA	25	37.8	48.6	49.2	40.2	90.5	45.1	31.6	—	16.1	14.4
EV/Sales	6.49	8.41	9.33	11.1	10.3	9.48	9.98	9.61	—	5.25	4.66
Earnings yield	2.46%	1.63%	1.07%	0.47%	1.2%	0.03%	0.78%	1.43%	—	3.59%	4.04%
FCF yield	1.32%	1.11%	0.65%	0.2%	0.84%	1.14%	1.72%	1.57%	—	3.04%	1.9%
PEG	—	—	—	—	—	—	—	—	—	—	13

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	82.1%	80.8%	77.7%	79.8%	80.1%	66.8%	72.1%	82%	81.1%	81.9%	83.6%
Operating margin	15.5%	9.13%	2.34%	7.13%	14.7%	-0.37%	10.2%	19%	19%	22.7%	23.5%
Net margin	14.8%	12.8%	9.28%	5.03%	11.8%	0.31%	7.42%	13%	13%	17.4%	17%
ROE	20.4%	17.2%	14.6%	8.41%	20.1%	0.29%	8.89%	15.2%	17.2%	21%	22%
ROA	5.45%	4.53%	3.38%	2%	4.71%	0.11%	3.41%	5.9%	6.77%	8.97%	8.02%
ROIC	12.4%	6.86%	1.87%	5.18%	11.2%	-0.22%	7.51%	12.2%	12.7%	15.2%	14.9%
Return on tangible assets	-21.3%	-22.6%	-30.7%	-33.8%	274.6%	-0.59%	-15.1%	-39.3%	-56.9%	-249.5%	-529.3%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	0.87	0.8	0.96	0.86	0.96	1.16	0.86	0.82	0.93	0.94	0.89
Quick ratio	0.72	0.62	0.78	0.68	0.76	0.76	0.68	0.64	0.74	0.72	0.67
Debt / equity	1.01	1.07	1.36	1.25	1.3	0.78	0.79	0.73	0.74	0.6	0.64
Debt / assets	0.27	0.28	0.32	0.3	0.31	0.29	0.3	0.28	0.29	0.26	0.28
Net debt / EBITDA	1.84	2.65	3.19	2.18	1.81	6.22	2.34	1.64	1.58	1.22	1.33
Interest coverage	3.6	2.64	2.46	2.1	4.08	0.79	2.88	5.34	6.17	8.68	8.21
Effective tax rate	4.11%	0%	0%	20.7%	19.7%	0%	0%	13.6%	19%	17.5%	16.9%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	9.09	8.87	8.72	9.37	10.1	13.2	14.3	14.8	34.9	37.9	39.6
EPS (basic)	1.39	1.19	0.85	0.52	1.22	0.04	1.06	1.92	4.54	6.6	6.6
EPS (diluted)	1.38	1.19	0.85	0.52	1.22	0.04	1.05	1.91	4.5	6.54	6.73
Book value per share	6.59	6.57	5.54	5.61	5.96	13.9	12	12.6	26.4	31.4	32.4
FCF per share	0.72	0.77	0.49	0.2	0.84	1.33	2.34	2.12	4.69	5.59	3.87
Cash per share	2.3	1.8	2.21	2.39	3.05	2.26	2.02	1.89	3.56	3.69	3.2
Capex per share	0.54	0.49	0.41	0.36	0.33	0.38	0.26	0.4	1.21	—	—

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	5.93%	5.53%	4.67%	3.86%	3.21%	2.88%	1.82%	2.68%	3.46%	—	—
Capex / operating cash flow	30.5%	47.8%	52.8%	70.6%	26.7%	63.7%	14.1%	19.6%	22.1%	—	—
Payout ratio	104.6%	122.7%	170%	292.7%	113.6%	3.4K%	132.5%	75.2%	65.7%	48.6%	47.4%
Dividend yield	2.58%	2%	1.81%	1.38%	1.36%	1.17%	1.04%	1.07%	—	1.74%	2.59%

Yield

2.59%

trailing twelve months

Frequency

Semi-annual

Last dividend

$2.153

ex-dividend Feb 19, 2026

Payout ratio

47%

of earnings

Dividend growth

2 years

consecutive annual raises

Dividend per share

Split-adjusted payout per share by ex-dividend date.

Recent payouts

Ex-dividend	Amount
Feb 19, 2026	$2.153
Aug 8, 2025	$0.515
Feb 21, 2025	$1.05
Aug 9, 2024	$0.50
Feb 22, 2024	$0.985
Aug 10, 2023	$0.465

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	$11.5B	$12B	$12.7B	$12.9B	$13.6B	$14.9B	$13.6B	$14.5B	$15.2B	$15.5B	$15.3B	$15.4B
YoY change	+4.64%	+7.29%	+16.5%	+13.3%	+18%	+23.8%	+7.17%	+11.7%	+12%	+4.11%	+12.5%	+6.41%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	5.8B	4.6B	5.6B	6.2B	8B	6.4B	6.2B	5.9B	5.5B	5.7B
Receivables	2.6B	2.8B	3B	3.6B	3.8B	6B	7.2B	8.4B	8.3B	10.2B
Inventory	2.3B	3B	2.9B	3.2B	4B	9B	4.7B	5.4B	5.3B	6.6B
Total current assets	13.3B	13.2B	15.6B	15.6B	19.5B	26.2B	22.6B	25.1B	25.8B	28.7B
Property, plant & equipment	6.8B	7.6B	7.4B	8.3B	8.2B	9B	8.3B	9.2B	10.1B	12.7B
Goodwill & intangibles	78.5B	76B	67.3B	65B	65.6B	124.8B	118.3B	116.3B	116.4B	118.2B
Total assets	62.5B	63.4B	60.7B	61.4B	66.7B	105.4B	96.5B	101.1B	104B	114.1B
Accounts payable	1.7B	2.3B	1.7B	1.8B	2.4B	2.8B	2.5B	3.3B	3.6B	3.8B
Short-term debt	2.3B	2.2B	1.8B	2B	2.4B	1.9B	5.5B	5.4B	2.5B	3B
Total current liabilities	15.3B	16.4B	16.3B	18.1B	20.3B	22.6B	26.3B	30.5B	27.9B	30.6B
Long-term debt	14.5B	15.6B	17.4B	16.2B	18B	28.9B	23.7B	23.2B	27.6B	26.1B
Total liabilities	45.9B	46.7B	46.6B	46.8B	51.1B	66.1B	59.4B	62B	63.2B	65.4B
Shareholders' equity	16.7B	16.6B	14B	14.6B	15.6B	39.3B	37.1B	39.2B	40.9B	48.7B
Total debt	16.8B	17.8B	19.1B	18.2B	20.4B	30.8B	29.2B	28.6B	30.1B	29.1B
Net debt	11.9B	14.5B	14.4B	12.9B	12.5B	24.5B	23.1B	22.8B	24.6B	23.4B

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	5.1B	5.9B	8B	7.1B	4.9B	5.7B	5.4B	7.1B	8.2B	5.7B	7.7B	5B
Receivables	11.3B	8.4B	11.1B	11B	11.9B	13B	13.3B	14.2B	14.3B	10.2B	14.1B	14.3B
Inventory	5.3B	5.4B	5.3B	5.7B	5.7B	5.3B	5.9B	6.5B	6.6B	6.6B	6.6B	6.9B
Total current assets	22.5B	25.1B	25.6B	25.4B	24.2B	25.8B	26.1B	28.9B	29.9B	28.7B	29.6B	28B
Property, plant & equipment	9.7B	9.2B	10.6B	10.8B	11.5B	11.6B	12.3B	13.2B	13.8B	12.7B	14.9B	16.3B
Goodwill & intangibles	115.3B	116.3B	117.6B	121B	121.1B	116.4B	117.4B	118.3B	118.8B	118.2B	116.2B	117.8B
Total assets	96.1B	101.1B	102.3B	104.3B	104.9B	104B	106.3B	112.4B	114.5B	114.1B	114B	115.8B
Accounts payable	20.5B	3.3B	19.7B	20.5B	21.7B	22.5B	22.5B	24B	25B	3.8B	22.5B	22.9B
Short-term debt	5.6B	5.4B	6.3B	5.4B	1.6B	2.5B	3.4B	6.9B	6.6B	3B	8B	6.2B
Total current liabilities	28.6B	30.5B	28.9B	28.6B	25.9B	27.9B	29.1B	33.5B	34.1B	30.6B	32.6B	31.6B
Long-term debt	23B	23.2B	28.2B	28.2B	30B	27.6B	27.9B	26B	26.1B	26.1B	26B	26B
Total liabilities	58.9B	62B	64.8B	64.7B	64.1B	63.2B	65.1B	67.6B	68.5B	65.4B	66.6B	65.5B
Shareholders' equity	37.2B	39.2B	37.5B	39.6B	40.8B	40.9B	41.1B	44.8B	46B	48.7B	47.4B	50.4B
Total debt	28.6B	28.6B	34.6B	33.5B	31.6B	30.1B	31.3B	32.8B	32.6B	29.1B	33.9B	32.2B
Net debt	23.7B	22.8B	26.7B	26.6B	26.8B	24.6B	26.1B	25.8B	24.5B	23.4B	26.4B	27.3B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	3.6B	2.2B	2B	1.5B	3.9B	-265M	2.5B	6.9B	8.7B	12.4B
Depreciation & amortization	—	—	—	—	—	—	—	—	—	—
Stock-based compensation	—	—	—	—	—	—	—	—	—	—
Change in working capital	1.3B	-465M	-536M	-1.2B	-1.4B	616M	2.6B	-2.1B	-1.8B	-2.5B
Operating cash flow	4.5B	2.6B	2B	1.3B	3.2B	1.7B	5.7B	6.3B	8.5B	14.6B
Capital expenditure	-1.4B	-1.2B	-1B	-942M	-855M	-1.1B	-809M	-1.2B	-1.9B	—
Investing cash flow	-7.2B	-5B	-1.2B	-1.4B	362M	-10.6B	-2B	-2.2B	-5.8B	-1.3B
Dividends paid	-3.6B	-3.5B	-3.5B	-3.6B	-3.6B	-3.9B	-4.4B	-4.5B	-4.6B	-5B
Share repurchases	—	—	—	—	—	—	—	—	—	—
Financing cash flow	-1.3B	-2.9B	-2B	-1.6B	-2B	3.9B	-6.6B	-6.3B	-3.7B	-7.2B
Net change in cash	-4B	-5.3B	-1.3B	-1.6B	1.6B	-5B	-2.8B	-2.3B	-1B	6.1B
Free cash flow	1.8B	2B	1.2B	509M	2.2B	3.8B	7.2B	6.6B	7.3B	8.7B

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	1.7B	897M	2.8B	2.4B	1.8B	1.7B	3.4B	3.1B	3.2B	2.6B	3.9B	2.8B
Depreciation & amortization	—	—	—	—	—	—	—	—	—	—	—	—
Stock-based compensation	—	—	—	—	—	—	—	—	—	—	—	—
Change in working capital	—	—	—	—	—	—	—	—	—	—	—	—
Operating cash flow	1.9B	1.8B	2.4B	3.1B	2.7B	2B	3.7B	3.7B	5.1B	2.3B	3.4B	2.9B
Capital expenditure	-314M	-524M	-364M	-382M	-417M	-706M	-428M	-650M	—	—	—	—
Investing cash flow	-735M	-738M	-1.4B	-2.7B	-680M	-1B	-789M	-991M	-361M	-275M	-374M	7M
Dividends paid	-1.4B	-2M	-3B	-17M	-1.6B	-3M	-3.3B	-10M	-1.6B	-3M	-3.3B	-1M
Share repurchases	0	—	—	—	—	—	—	—	—	—	—	—
Financing cash flow	-2.7B	-217M	2.1B	-1.1B	-4B	-588M	-2.6B	702M	-2B	-3.2B	267M	-2.4B
Net change in cash	-1.5B	869M	3.2B	-746M	-2.1B	408M	284M	3.5B	2.8B	-1.1B	3.3B	462M
Free cash flow	2.2B	1.4B	881M	2.4B	2B	2B	2.7B	1.5B	3.4B	1.1B	1.8B	-240M

Date	Ratio
Feb 2, 2026	1:2
Jul 27, 2015	2:1
Apr 8, 1998	3:1

AstraZeneca PLC American Depositary Shares Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Dividend per share

Recent payouts

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement

Split history